Neo Ivy Capital Management Royalty Pharma PLC Transaction History

Neo Ivy Capital Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$29.6 - $36.56 $945,631 - $1.17 Million	31,947 Added 455.47%	38,961 $1.2 Million
Q4 2022 Mar 24, 2023	BUY	$39.17 - $44.04 $25,852 - $29,066	660 Added 10.39%	7,014 $277,000
Q3 2022 Nov 15, 2022	BUY	$39.88 - $44.65 $253,397 - $283,706	6,354 New	6,354 $255,000
Q2 2022 Aug 16, 2022	SELL	$37.53 - $44.22 $251,150 - $295,920	-6,692 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$37.46 - $42.44 $250,682 - $284,008	6,692 New	6,692 $260,000
Q4 2021 Feb 15, 2022	SELL	$35.17 - $42.48 $38,757 - $46,812	-1,102 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$36.14 - $42.24 $39,826 - $46,548	1,102 New	1,102 $54,000
Q1 2021 Oct 07, 2021	SELL	$42.34 - $52.82 $242,862 - $302,975	-5,736 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.12 - $50.05 $141,301 - $195,795	3,912 Added 214.47%	5,736 $287,000
Q3 2020 Nov 17, 2020	BUY	$38.56 - $48.36 $70,333 - $88,208	1,824 New	1,824 $76,000
Q2 2020 Aug 17, 2020	SELL	$44.5 - $52.11 $49,039 - $57,425	-1,102 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$44.5 - $52.11 $49,039 - $57,425	1,102 New	1,102 $54,000

413

283M

578K

47.5K

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $10.6B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.